Publications by authors named "N Reguart"
Purpose: To determine the effectiveness of uni- or multimodal prehabilitation on several outcomes in patients undergoing neoadjuvant therapy before cancer surgery.
Methods: A systematic search was carried on May 1, 2023, using four major databases (SCOPUS, Web of Science, Medline (Ovid and Pubmed)) and updated monthly until February 2024. Inclusion criteria included (i) any original articles (any design), (ii) adult patients undergoing neoadjuvant therapy (NAT) prior to surgical resection, (iii) participation in uni- or multimodal prehabilitation programs during NAT, and (iv) reporting on any functional, treatment-related, or perioperative outcome.
Article Synopsis
- The study focused on pairing naporafenib, a pan-RAF inhibitor, with either rineterkib or trametinib to treat patients with non-small cell lung cancer (NSCLC) and certain genetic mutations.
- Conducted on 216 patients, the research aimed to find safe and effective dosage levels, identifying recommended doses while monitoring for side effects and antitumor activity.
- Results showed dose-limiting toxicities in 16% of patients, with some achieving partial responses; the study established specific dosages that were well-tolerated along with noticeable reductions in certain mRNA levels.
Background: Capmatinib has previously shown activity in treatment-naive and previously treated patients with non-small-cell lung cancer (NSCLC) and a MET exon 14-skipping mutation (METex14). Here, we report the final outcomes from the phase 2 GEOMETRY mono-1 study with an aim to provide further evidence for the activity of capmatinib.
Methods: In this non-randomised, multi-cohort, open-label, phase 2 trial conducted in 152 centres and hospitals in 25 countries, with patients treated in 95 centres in 20 countries, eligible patients (aged ≥18 years) with MET-dysregulated, EGFR wild-type, and ALK rearrangement-negative advanced NSCLC (stage IIIB/IV) and an Eastern Cooperative Oncology Group performance status of 0 or 1 were assigned to cohorts (1a, 1b, 2, 3, 4, 5a, 5b, 6 and 7) based on their MET status (METex14 or MET amplification) and previous therapy lines.
Article Synopsis
- Immunotherapy treatments show high effectiveness in advanced non-small-cell lung cancer (NSCLC), but the impact of BRAF mutations in these cases is unclear.
- In a study of 116 stage IIIA/B and 84 stage IV patients, BRAF mutations were found in a small percentage, with all patients who had these mutations remaining alive and disease-free at the study's cutoff.
- BRAF-mutated patients had a 100% pathological complete response rate to neoadjuvant chemoimmunotherapy compared to a 44.3% rate in BRAF wild-type patients, suggesting that BRAF mutations could indicate better outcomes for those undergoing immunotherapy.
Article Synopsis
- * A study was conducted with 38 fusion-positive NSCLC samples, comparing NGS with FISH and RT-PCR, revealing that while NGS identified all cases, some fusions were missed by FISH and RT-PCR, highlighting limitations in these lesser methods.
- * The findings suggest that understanding the strengths and weaknesses of different testing techniques is crucial for improving clinical protocols, reinforcing the need for NGS as the primary approach to ensure accurate fusion detection